Read next
November 08, 2017
1 min read
Save
Trial Scorecard: PACIFY
Issue: November 2017
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Study evaluated effects of anacetrapib (Merck) to reduce risk for MI, coronary death or coronary revascularization in patients with atherosclerotic vascular disease taking statin therapy.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
